BGI Genomics Co., Ltd. (SHE:300676)
China · Delayed Price · Currency is CNY 50.36
+0.06 (0.12%)
Feb 4, 2026, 3:04 PM CST
BGI Genomics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,690 | 3,842 | 4,333 | 7,036 | 6,754 | 8,387 |
Other Revenue | 24.6 | 24.6 | 16.91 | 16.67 | 11.75 | 10.31 |
| 3,715 | 3,867 | 4,350 | 7,053 | 6,766 | 8,397 | |
Revenue Growth (YoY) | -7.87% | -11.10% | -38.33% | 4.24% | -19.42% | 199.86% |
Cost of Revenue | 2,341 | 2,364 | 2,202 | 3,528 | 2,845 | 3,382 |
Gross Profit | 1,374 | 1,503 | 2,147 | 3,526 | 3,921 | 5,015 |
Selling, General & Admin | 1,261 | 1,424 | 1,441 | 1,998 | 1,637 | 1,630 |
Research & Development | 536.18 | 601.38 | 523.23 | 526.46 | 474.79 | 611.32 |
Other Operating Expenses | 28.39 | 16.77 | 4.1 | -89 | 24.06 | -10.23 |
Operating Expenses | 2,105 | 2,240 | 2,035 | 2,620 | 2,241 | 2,372 |
Operating Income | -730.7 | -736.53 | 112.94 | 905.27 | 1,680 | 2,643 |
Interest Expense | -25.72 | -52.02 | -91.56 | -100.76 | -104.72 | -89.04 |
Interest & Investment Income | 118.61 | 125.72 | 153.33 | 424.36 | 218.16 | 119.22 |
Currency Exchange Gain (Loss) | -19.09 | -19.09 | -11.36 | -2.27 | -39.76 | -138.51 |
Other Non Operating Income (Expenses) | 4.06 | -3.41 | -35.86 | -91.43 | -4.04 | -35.45 |
EBT Excluding Unusual Items | -652.83 | -685.33 | 127.49 | 1,135 | 1,750 | 2,499 |
Impairment of Goodwill | -10.64 | -10.64 | - | - | - | - |
Gain (Loss) on Sale of Investments | -34.78 | -87.41 | -34.36 | 80.73 | 86.41 | 52.2 |
Gain (Loss) on Sale of Assets | -2.29 | -0.63 | 2.76 | 0.11 | -3.88 | -4.23 |
Asset Writedown | -128.44 | -125.97 | -9.25 | -209.24 | -102.24 | -105.02 |
Other Unusual Items | 23.86 | 23.86 | 28.89 | 0.02 | 15.87 | 0 |
Pretax Income | -805.11 | -886.11 | 115.54 | 1,007 | 1,746 | 2,442 |
Income Tax Expense | 9.04 | 25.99 | 21.85 | 197.51 | 268.19 | 340.24 |
Earnings From Continuing Operations | -814.15 | -912.1 | 93.68 | 809.29 | 1,478 | 2,102 |
Minority Interest in Earnings | 14.24 | 9.41 | -0.78 | -6.52 | -16.16 | -11.77 |
Net Income | -799.91 | -902.69 | 92.9 | 802.77 | 1,462 | 2,090 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 1.4 |
Net Income to Common | -799.91 | -902.69 | 92.9 | 802.77 | 1,462 | 2,089 |
Net Income Growth | - | - | -88.43% | -45.07% | -30.08% | 656.43% |
Shares Outstanding (Basic) | 415 | 412 | 410 | 410 | 410 | 398 |
Shares Outstanding (Diluted) | 415 | 412 | 412 | 410 | 412 | 399 |
Shares Change (YoY) | 2.32% | 0.01% | 0.48% | -0.32% | 3.11% | -0.20% |
EPS (Basic) | -1.93 | -2.19 | 0.23 | 1.96 | 3.56 | 5.25 |
EPS (Diluted) | -1.93 | -2.19 | 0.23 | 1.96 | 3.55 | 5.24 |
EPS Growth | - | - | -88.48% | -44.90% | -32.25% | 658.65% |
Free Cash Flow | -638.84 | -433.76 | -827.62 | -1,136 | 2,093 | 3,302 |
Free Cash Flow Per Share | -1.54 | -1.05 | -2.01 | -2.77 | 5.08 | 8.27 |
Dividend Per Share | - | - | 0.100 | 1.000 | 0.350 | 0.350 |
Dividend Growth | - | - | -90.00% | 185.71% | - | 250.00% |
Gross Margin | 36.99% | 38.87% | 49.37% | 49.99% | 57.95% | 59.72% |
Operating Margin | -19.67% | -19.05% | 2.60% | 12.83% | 24.83% | 31.48% |
Profit Margin | -21.53% | -23.34% | 2.14% | 11.38% | 21.60% | 24.88% |
Free Cash Flow Margin | -17.20% | -11.22% | -19.03% | -16.10% | 30.93% | 39.32% |
EBITDA | -280.81 | -320.95 | 482.76 | 1,262 | 1,959 | 2,945 |
EBITDA Margin | -7.56% | -8.30% | 11.10% | 17.90% | 28.95% | 35.08% |
D&A For EBITDA | 449.89 | 415.57 | 369.81 | 357.13 | 278.78 | 302.33 |
EBIT | -730.7 | -736.53 | 112.94 | 905.27 | 1,680 | 2,643 |
EBIT Margin | -19.67% | -19.05% | 2.60% | 12.83% | 24.83% | 31.48% |
Effective Tax Rate | - | - | 18.92% | 19.62% | 15.36% | 13.93% |
Revenue as Reported | 3,715 | 3,867 | 4,350 | 7,053 | 6,766 | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.